Stage 4 melanoma is not reliably curable in the traditional sense, but a meaningful fraction of patients now achieve durable remissions lasting a decade or more, something that was nearly unheard of before 2011. As recently as the early 2010s, the median survival after a stage 4 melanoma diagnosis was roughly six to eight months, and chemotherapy offered no clear survival benefit.1American Society of Clinical Oncology Educational Book. Curing Stage IV Melanoma: Where Have We Been and Where Are We? The arrival of immune checkpoint inhibitors and targeted drugs has rewritten that prognosis so dramatically that oncologists now debate whether the word “cure” applies to some of these long-term survivors.
What Stage 4 Actually Means
Stage 4 melanoma means the cancer has spread beyond the original skin site and nearby lymph nodes to distant organs. The most common destinations are the lungs, liver, bones, and brain. Within stage 4, there are subcategories based on where the metastases land and whether a blood marker called lactate dehydrogenase (LDH) is elevated. Under the current staging system, a separate designation, M1d, exists specifically for melanoma that has reached the central nervous system.2PubMed Central. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual Both the location of distant disease and the LDH level influence prognosis, with brain metastases and elevated LDH historically carrying the worst outlook.3PubMed. The new melanoma staging system
How Immunotherapy Changed the Survival Curve
The transformation of stage 4 melanoma outcomes is largely the story of immune checkpoint inhibitors. These drugs release the brakes that cancer cells put on the immune system, allowing the body’s own T cells to attack the tumor. The combination of nivolumab and ipilimumab has become the benchmark against which other treatments are measured.
A landmark trial followed patients with advanced melanoma for a minimum of ten years. Median overall survival for patients receiving the nivolumab-plus-ipilimumab combination was about 72 months, or roughly six years. In the group receiving nivolumab alone, it was about 37 months. Ipilimumab by itself offered a median of about 20 months. Among patients on the combination, melanoma-specific survival had not been reached at the ten-year mark, with over 37% of that group still alive at the study’s close.4PubMed Central. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma At five years, roughly half of patients on the combination and 44% on nivolumab alone were still alive.5PubMed. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
What makes these numbers especially striking is the shape of the survival curve. In the combination group, patients who were progression-free at three years had a ten-year melanoma-specific survival rate of 96%.4PubMed Central. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma In other words, if the disease had not progressed in the first three years, the chance of dying from melanoma over the next seven years was vanishingly small. That pattern is what has pushed oncologists toward language like “functional cure” for a subset of patients.
Pembrolizumab, another widely used checkpoint inhibitor, tells a similar story. In the KEYNOTE-001 trial, the five-year overall survival rate was about 34% across all patients and 41% among those who had not received prior treatment. Most responses were still ongoing at the time of data analysis, with the longest lasting over five years.6Annals of Oncology. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
Patients with BRAF-mutant tumors may do somewhat better. At a minimum follow-up of six and a half years, survival rates were 57% for BRAF-mutant patients on the nivolumab-ipilimumab combination, compared to 46% for those whose tumors lacked that mutation.7PubMed Central. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Targeted Therapy for BRAF-Mutant Melanoma
About 40-50% of cutaneous melanomas carry a mutation in the BRAF gene, most commonly the V600E variant. This mutation drives a signaling pathway that tells cells to grow and divide, and drugs that block this pathway can shrink tumors quickly. The standard approach pairs a BRAF inhibitor with a MEK inhibitor, targeting two points in the same signaling chain.
In a trial comparing the combination of dabrafenib and trametinib against dabrafenib alone, the combination produced responses in about two-thirds of patients. At six months, 93% of patients on the combination were alive, compared to 85% on dabrafenib alone.8PubMed. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma The responses tend to be fast and dramatic, which matters when someone has bulky disease threatening organ function.
The downside is durability. In a large real-world study of 435 patients treated with BRAF-MEK inhibitors, the median time before disease progressed was eight months, and median overall survival was about 12 months. Only about one in five patients survived to the four-year mark.9PubMed Central. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors Resistance almost always develops. Research shows melanoma cells can amplify the BRAF mutation itself or combine multiple escape mechanisms to reactivate the growth pathway even while both drugs are present.10Cancer Cell. Acquired Resistance to Combined BRAF and MEK Inhibition Parallels Clonal Evolution in Melanoma
Because of this resistance problem, targeted therapy is often viewed as a bridge rather than a standalone cure. It buys time and controls symptoms while the treatment plan evolves, and many patients eventually switch to or incorporate immunotherapy.
Sequencing Immunotherapy and Targeted Therapy
For patients whose melanoma carries a BRAF mutation, one of the most debated treatment decisions is what to start with: immunotherapy, targeted therapy, or some deliberate alternation between the two. The SECOMBIT trial tested three approaches in previously untreated patients with BRAF-mutant stage 4 melanoma. One arm started with targeted therapy and switched to immunotherapy at progression. Another did the reverse. A third gave a short course of targeted therapy upfront, then switched to immunotherapy, and returned to targeted therapy if needed.11PubMed. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
A nationwide real-world study with nearly 200 patients failed to identify a clearly superior sequencing strategy. Patients who received both classes of drugs in sequence survived longer than those who only got one, but there was no significant overall survival difference between starting with immunotherapy versus starting with targeted therapy.12PubMed Central. Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma The practical takeaway for patients: if your melanoma is BRAF-mutant, you have options, and the sequencing decision should be driven by clinical circumstances like how fast the disease is growing and how well your organs are holding up, rather than a rigid protocol.
When Treatment Can Stop
One of the questions patients ask most urgently is whether they will need treatment forever. The evidence increasingly suggests that for a fortunate group, the answer is no. A systematic review pooling data from patients who stopped immunotherapy found that one-year and three-year progression-free survival rates after stopping were about 86% and 71%, respectively. Overall survival at three years after discontinuation was roughly 86% as well.13PubMed Central. Survival after cessation of immunotherapies in melanoma: A systematic review and meta‐analysis Patients who elected to stop treatment fared better than those who stopped because of toxicity, and longer treatment duration was associated with better outcomes after cessation.
The general guidance taking shape among melanoma specialists is that stopping anti-PD-1 therapy after a confirmed complete response and at least six months of treatment is reasonable, with durable remissions observed in more than 85% of patients who meet that bar.14Nature Reviews Clinical Oncology. Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm Among those who do relapse after stopping, it tends to happen more than two years out, and retreatment can work. In one study, only about 9-10% of patients who stopped checkpoint inhibitors after a complete remission eventually relapsed, and retreatment was feasible, though side effects were common.15The Oncologist. Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission
This is where the “cure” question gets philosophical. If you achieve a complete response, stop all treatment, and remain cancer-free for a decade, most people would call that cured. The medical community is more cautious with the word because late relapses can occur, but functionally, the growing population of ten-year survivors is living proof that long-term disease control, whatever label you attach, is real and achievable for some.
Brain Metastases
Melanoma has a particular tendency to spread to the brain, and brain metastases have historically been among the most feared complications. Modern treatment has improved this scenario as well, though outcomes remain worse than for patients without brain involvement.
A study of patients with melanoma brain metastases treated with ipilimumab combined with stereotactic radiosurgery found three-year survival rates of about 39-50%, with survival from the time of stage 4 diagnosis reaching roughly 29-33 months. Several patients maintained good functional status throughout.16PubMed Central. Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery In a separate analysis of patients receiving stereotactic radiosurgery alongside systemic therapy, those on anti-PD-1 drugs had a median survival of about 20 months, compared to about 18 months with BRAF-targeted therapy and roughly eight months with ipilimumab alone.17PubMed. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies These numbers would have been almost unimaginable a decade ago, when the diagnosis of melanoma brain metastases typically carried a prognosis measured in weeks.
Subtypes That Respond Differently
Not all melanomas behave the same, and the prognosis picture described above applies mainly to the most common form: cutaneous melanoma arising from sun-exposed skin. Other subtypes have distinct biology and, unfortunately, tend to respond less well to current treatments.
Mucosal melanoma, which develops on internal surfaces like the nasal passages, mouth, or genital tract, carries the poorest prognosis among subtypes. From the time of first metastasis, median survival has been reported at about nine months for mucosal melanoma, compared to roughly 12 months for cutaneous types.18PubMed Central. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis After checkpoint inhibitor treatment, the gap persists: patients with cutaneous primaries had a median survival of 45 months, while mucosal and acral subtypes survived a median of 17-18 months, and uveal melanoma just 12 months.19PubMed Central. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
Uveal melanoma, which arises in the eye, is particularly resistant to immunotherapy. In one analysis, no tumor responses were observed in uveal melanoma patients treated with checkpoint inhibitors, and overall survival with immunotherapy was not significantly different from chemotherapy.20PubMed Central. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma This is thought to relate to the lower mutational burden of uveal melanoma, which gives the immune system fewer targets. Different treatment strategies are being explored specifically for this subtype, including liver-directed therapies, since uveal melanoma metastasizes to the liver with near-universal frequency.
Newer Drug Combinations
The field has not stopped at nivolumab and ipilimumab. A newer combination pairs nivolumab with relatlimab, a drug targeting a different immune checkpoint called LAG-3. In the RELATIVITY-047 trial, this combination doubled median progression-free survival compared to nivolumab alone, from about five months to about ten months. With longer follow-up, median overall survival was 51 months with the combination versus 34 months with nivolumab alone.21PubMed Central. Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047 While the overall survival improvement did not reach statistical significance in the formal analysis, the trend is clinically meaningful and represents a potential alternative for patients who may not tolerate the high toxicity profile of the nivolumab-ipilimumab combination.22PubMed Central. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
For patients whose melanoma has progressed through checkpoint inhibitors and targeted therapy, tumor-infiltrating lymphocyte (TIL) therapy offers another route. This approach harvests immune cells directly from a patient’s tumor, expands them in a laboratory, and infuses them back. Response rates of 30-50% have been consistently observed in heavily pretreated patients, a group with few remaining options.23PubMed Central. Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future The first approved TIL product, lifileucel, produced an overall response rate of about 31% in this population, and nearly 42% of responses lasted at least 18 months.24PubMed Central. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Oncolytic virus therapy adds yet another dimension. Talimogene laherparepvec (T-VEC) is a modified herpes virus injected directly into melanoma lesions. It kills tumor cells and triggers a broader immune response. In combination trials with checkpoint inhibitors, T-VEC paired with pembrolizumab produced a confirmed overall response rate of 67% with a complete response rate of 43%.25PubMed Central. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma Real-world data showed a one-year overall survival rate of 80% in patients receiving T-VEC with systemic immunotherapy, with responses observed in both injected and distant non-injected lesions.26Journal of Clinical Oncology. Talimogene laherparepvec with systemic immunotherapy in melanoma: A real-world experience
Neoadjuvant Immunotherapy Before Surgery
One of the most exciting shifts in melanoma treatment is using immunotherapy before surgery rather than only after it. The idea is that giving the immune system a look at the intact tumor while checkpoint inhibitors are on board primes a stronger and more lasting immune response.
Early results are promising. In a Swedish real-world study of patients with resectable stage III or IV melanoma receiving neoadjuvant immunotherapy, about 42% achieved a major pathological response, meaning the surgery that followed found very little viable tumor remaining. Those patients had a 12-month recurrence-free survival of 94%, compared to 61% for patients whose tumors did not respond to the pre-surgery treatment.27PubMed. Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma – A Swedish retrospective real-world study (NEO-MEL) A larger nationwide population-based cohort confirmed similar numbers: major pathological response in 43% of patients, with estimated two-year overall survival of 87% and a strong link between pathological response and long-term outcome.28PubMed. Neoadjuvant immunotherapy for resectable cutaneous melanoma: a nationwide population-based cohort This approach may eventually change the conversation for some stage 4 patients with limited metastatic disease that can be surgically removed.
Biomarkers That Help Predict Who Will Respond
Not everyone responds equally to immunotherapy, and researchers are working to identify markers that predict who will benefit most. Tumor mutational burden, which reflects how many genetic changes exist in the tumor, tends to correlate with better responses to checkpoint inhibitors. Circulating tumor DNA, fragments of tumor genetic material floating in the bloodstream, and a soluble form of PD-L1 have also emerged as tools for gauging prognosis.29PubMed Central. A Complete Response in a Metastatic Melanoma Patient After a Single Dose of Dual Checkpoint Inhibitors Blockade Could Be Predictable: A Case Report
Circulating tumor DNA is increasingly being used as a real-time monitoring tool. In one study, patients who were positive for molecular residual disease based on circulating tumor DNA after surgery had dramatically shorter times to distant metastasis. Rising circulating tumor DNA levels during the first weeks of immunotherapy predicted treatment failure, while patients with undetectable levels remained progression-free for the duration of follow-up.30PubMed. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients This kind of monitoring could eventually help personalize how long patients stay on treatment and when it is safe to stop.
Liquid biopsies, blood tests that detect circulating tumor cells, cell-free tumor DNA, and microRNA, have shown potential for surveilling both stage III and stage IV patients for early signs of relapse, offering a less invasive alternative to repeated imaging.31PubMed Central. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients
Side Effects and the Cost of Long-Term Survival
Living longer with advanced melanoma comes with trade-offs. The same immune activation that destroys tumors can attack healthy tissues. Common immune-related side effects include inflammation of the colon, liver, thyroid, lungs, and skin. Most are manageable with steroids or temporary treatment pauses, but serious events occur. In one cohort study tracking late-onset severe side effects, cases of heart inflammation, liver inflammation, and optic nerve damage were documented more than two years after treatment started.32PubMed Central. Severe Late-Onset Grade III-IV Adverse Events under Immunotherapy: A Retrospective Study of 79 Cases The possibility of late toxicity means ongoing monitoring is necessary even after treatment stops.
Survivorship brings its own challenges. In a cross-sectional study of long-term stage 4 melanoma survivors, more than 40% reported persistent treatment-related complaints.33PubMed Central. Psychosocial distress and persistent adverse events in long-term survivors of stage IV melanoma – a cross-sectional questionnaire study Financial toxicity is another documented burden. Among advanced melanoma patients on immunotherapy, the financial strain of treatment was significantly correlated with worse quality of life across nearly every functional domain measured, including social, emotional, and physical well-being.34PubMed Central. The experience of financial toxicity among advanced melanoma patients treated with immunotherapy Immunotherapy regimens can cost tens of thousands of dollars per infusion cycle, and even patients with insurance may face substantial copays, missed work, and travel costs for treatment at specialized centers. These realities shape the lived experience of melanoma survival in ways that survival statistics alone do not capture.